NanoViricides, Inc. (NNVC)

$3.08

-0.08 (-2.53%)
Rating:
Recommendation:
Buy
Symbol NNVC
Price $3.08
Beta 0.954
Volume Avg. 0.60M
Market Cap 35.586M
Shares () -
52 Week Range 1.04-7.86
1y Target Est -
DCF Unlevered NNVC DCF ->
DCF Levered NNVC LDCF ->
ROE -30.70% Strong Sell
ROA -33.41% Strong Sell
Operating Margin -
Debt / Equity 1.56% Neutral
P/E -
P/B 1.44 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest NNVC news


Dr. Irach Taraporewala
Healthcare
Biotechnology
American Stock Exchange

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.